The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy
- 3 November 2009
- journal article
- review article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 10 (1) , 1-11
Abstract
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are well established in the treatment of hypercholesterolaemia and the prevention of coronary artery disease. Despite this, there is wide inter-individual variability in response to statin therapy, in terms of both lipid-lowering and adverse drug reactions. The major site of statin action is within hepatocytes and recent interest has focussed on genetic variation in hepatic influx and efflux transporters for their potential to explain these differences. In this review we explore current literature regarding the pharmacokinetic and pharmacodynamic influence of the common c.388A>G and c.521T>C single-nucleotide polymorphisms (SNPs) within the solute carrier organic anion transporter 1B1 (SLCO1B1) gene, encoding the organic anion transporter polypeptide 1B1 (OATP1B1) influx transporter. We discuss their potential to predict the efficacy of statin therapy and the likelihood that patients will experience adverse effects.Keywords
This publication has 54 references indexed in Scilit:
- No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatinBritish Journal of Clinical Pharmacology, 2009
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide StudyNew England Journal of Medicine, 2008
- The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15Pharmacogenetics and Genomics, 2008
- SLCO1B1 521T→C functional genetic polymorphism and lipid‐lowering efficacy of multiple‐dose pravastatin in Chinese coronary heart disease patientsBritish Journal of Clinical Pharmacology, 2007
- SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidPharmacogenetics and Genomics, 2006
- Statin Safety: A Systematic ReviewThe American Journal of Cardiology, 2006
- Clinical implications of pharmacogenomics of statin treatmentThe Pharmacogenomics Journal, 2006
- Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environmentClinical Pharmacology & Therapeutics, 2005
- An association study of 43 SNPs in 16 candidate genes with atorvastatin responseThe Pharmacogenomics Journal, 2005
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002